HIV Infections Clinical Trial
Official title:
Provision of HIV Self-Test Kit to Increase Uptake of HIV Testing Among Emergency Department Patients Who Decline Emergency Department-Based HIV Screening.
The proposed pilot research has three aims: 1) to determine the feasibility and acceptability of provision of HIV self-testing kit in order to increase uptake and engagement of HIV testing among emergency department patients who decline conventional emergency department HIV testing and to increase the engagement of HIV testing at a regular basis for those with an increased risk for HIV (the index participants); 2) to determine the uptake and engagement of HIV testing by provision of HIV self-testing kit; and 3) to determine the feasibility and acceptability of HIV self-testing kit referral among partners or peers of the index participants. The investigators will conduct a pilot randomized study at Johns Hopkins Hospital emergency department on (1) patients who decline routine HIV testing offer and (2) patients who are at an increased risk for HIV. The consented patient will be randomized to HIV self-testing kit group which the investigators will provide a free Food and Drug Administration-approved HIV self-testing home kit for the participant to take it home or to reference group which the investigators will not provide the self-testing kit. Consented patients in both groups will fill out a short survey regarding their socio-demographic information as well as their experience and perceptions regarding HIV testing. For patients who are in the HIV self-testing kit group, they will be asked if they would like to take a free HIV self-testing home kit home. Participants in this group will also receive information regarding how to access "I Want The Kit" website to report the completion of HIV self-testing at home. For patients who are in the reference group, a standard pamphlet regarding the importance of HIV testing and HIV testing venues in Baltimore City used by emergency department-based HIV testing program will be provided to the patients. Follow-up questionnaires will inquire regarding the patient's experience regarding HIV testing since their index visit. When the participants in the HIV self-testing kit group in Aim 1, they will also be provided 5 referral cards for their partners and peers for them to request a free HIV self-testing kit from the "I Want The Kit" website. At the 1-month phone follow-up, the investigators will ask participants if they are able to give the referral cards to their partner(s) or friend(s), how they think if their partner(s) and/or friend(s) will request an HIV self-testing kit from the "I Want The Kit" website.
The Investigators will conduct a pilot randomized study at Johns Hopkins Hospital Emergency Department on patients who decline routine HIV testing offer by triage nurses. 1. Recruitment "Refusers" Cohort Study staff will screen the emergency department tracking board (Epic) for patients who meet study enrollment criteria, which is done routinely as part of the emergency department HIV testing program. When an eligible patient is identified by the chart review (please see HIPAA form 4), the study staff will talk to the emergency department clinician regarding research opportunity for the potentially eligible patients. For all individuals who are not clinical patients of a study team member, the recruitment procedure will be that the patient's clinician will request and document in the chart the patient's permission to be contacted by the research staff. "High Risk" Cohort "The eligibility of "high-risk cohort" is emergency department patients who are offered an HIV test as the standard of care in the emergency department, accept the standard of care (SOC) HIV testing, and who have at increased risk for HIV. Study staff will screen the emergency department tracking board (Epic) for patients who are offered an HIV test at triage by the triage nurse, which is done routinely as part of the emergency department HIV testing program. When an eligible patient is identified by the chart review (please see HIPAA form 4), the study staff will talk to the emergency department clinician regarding research opportunity for the potentially eligible patients. For all individuals who are not clinical patients of a study team member, the recruitment procedure will be that the patient's clinician will request and document in the chart the patient's permission to be contacted by the research staff. In order to determine if the patient is at increased risk for HIV, the study staff will use of the Screening Question (three screening questions) that is uploaded in the application section 20 (see section 20 for Screening_Question_05312016"). The three questions are as follows: 1) Have you been sexually active in the past 12 months, 2) have you ever used injection drugs in your life, and 3) (for men only), have you ever had sex with a man in your life time. If the patient responds "yes" to the question "Is any of your answer "Yes" (see section 20 for Screening_Question_05312016"), they will be considered eligible and will then go through the consent and enrollment procedures. No identifiers will be collected for this screening step. 2. Enrollment The study staff will obtain verbal informed consent. The process will involve a description of the study as provided in the verbal consent form (OralConsentScript_for_HighRiskPatient_06012016.docx) with a chance to provide answers to any questions about the study. Justification for verbal consent is provided in the e-Institutional Review Board application. Specifically, this study involves no bodily intervention and poses minimal risk to patients. The consent process will take between approximately 5-10 minutes, but as much time as needed will be provided to patients. Consented subjects will be given a copy of the oral consent document for their information and records. In this consent, the patient will be asked for permission to review their medical charts at Johns Hopkins Hospital for the clinical information of their emergency department visit. Consented patients will be randomized to one of two groups, the Index Group (Group 1) or the Reference Group (Group 2). The index group or the HIV self-testing kit group will be provided a free FDA-approved HIV self-testing home kit (OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test) and the reference group will not receive the HIV self-testing kit. Consented patients in both groups will fill out a short survey regarding their socio-demographic information as well as their experience, attitudes, and perceptions regarding HIV testing. For patients who are in the HIV self-testing kit group, they will be asked if they would like to take a free FDA-approved HIV self-testing home kit home. If they agree, the research staff will make sure the patients will take the kit home when they are discharged. Participants in this group will also receive information regarding how to access the "I Want The Kit" website to report the completion of HIV self-testing at home. Participants in this group will also be informed of a lottery-based monetary compensation with 1 in 10 chance to win an additional $50 gift card for reporting the test results to the "I Want The Kit" website. Participant who wins the $50 gift card will be notified via text message, followed by a phone call while participant who does not win the gift card will be notified via text message (see section 20 for "Text Message Script for Lottery Incentive). For patients who are in the reference group, a standard pamphlet regarding the importance of HIV testing and HIV testing venues in Baltimore City used by current Johns Hopkins Hospital emergency department-based HIV testing program will be provided to the patients. 3. Survey information: - Patients will be consented and enrolled in the study prior to collecting data in the emergency department. - After patient consent and enrollment by the study staff, each study participant will complete a survey questionnaire (see attached Index_Questionnaire.docx in Supplemental Study Documents) at the time of enrollment to indicate their social, demographic, and clinical characteristics. The survey is research (not part of routine care), but would not add to the patient's length of stay since it can be conducted during waiting time in a private setting. This survey will be clearly explained by and completed with the assistance of the study staff. - All patients will be informed of intent to contact them for a brief follow-up phone interview at one month and 3 months from the date of enrollment. This is one of the exclusion criteria. - Following enrollment, a member of the research team will abstract chart data of the emergency department visits. The abstraction will focus on visit-specific clinical data (e.g. chief complaint, diagnosis, acuity level, and disposition (The full variable list can be found in section 20, Variable List). 4. Patient Follow-up - Participants will receive a phone or text message reminder from the study team in order to remind that they are enrolled in the study within a week after the enrollment. The study team will make sure that the participant is the one who answers the phone before reminding the participant of this study. The text message will not contain the words of HIV or HIV testing. The participant will also receive text message reminder 1 week before each follow-up time (1 and 3 month time point). The text message will include the reminder of the phone follow-up as well as the $10 gift card incentive that the investigators would be providing to the participant upon completing the phone follow up (see section 20 for "Text reminder version 0.02). - Consented patients will be contacted by the study team at one month and 3 months after enrollment. No more than five separate attempts to contact will be made during this time until deemed lost to follow up for the particular follow up time point. - Follow-up questionnaires will ask the patient about their experience, attitudes, and perceptions regarding HIV testing since their index visit. Please see attached Phone_Script.docx - A $10.00 gift card will be mailed to the participant once he/she completes the follow-up survey by phone for each follow up time point. 5. HIV Self-testing at home Instructions for performing the home test, with visual aids, will be included with the kit. For participants in the HIV self-testing kit group whose test result by HIV self-testing at home is interpreted as "reactive" or "indeterminate", he or she can follow the instruction inside the kit to call a hotline to Johns Hopkins Hospital emergency department routine rapid HIV screening and linkage to care program staff that operates 16 hours a day, 7 days a week, OraQuick Consumer Support Center that operates 24 hours a day, or their primary physician for counseling. Patients with a reactive test result can either come to Johns Hopkins Hospital emergency department or the Johns Hopkins HIV Women's Program to receive confirmatory blood testing of the screening self-test. All participants with a positive or indeterminate screening result will have blood drawn and sent to the Maryland Department of Health and Mental Hygiene Laboratories Administration Central Laboratory where free confirmatory testing will be performed using the HIV-1 Western Blot Assay from Bio-Rad Laboratories. (At Maryland Department of Health and Mental Hygiene and Central Laboratory, indeterminate and negative HIV-1 Western Blot specimens are tested using the Multispot HIV-1/HIV-2 Rapid test as a differentiation assay to rule out HIV-2, and using in-house validated HIV-1 real time polymerase chain reaction assay to detect acute cases of HIV-1). For participants in the HIV self-testing kit group, they will be asked to report their test result on to "I Want The Kit" website using the access information provided in the HIV self-testing kit. When the participants (the index participants) in the HIV self-testing kit group in Aim 1 receive the self-testing kit, they will also be provided 5 referral cards to give to their partners and peers in the drug, sex, and social networks for them to request a free HIV self-testing kit from the "I Want The Kit" website. On the referral card, a unique code number be used after the subject uses provided website address to land in "I Want The Kit" website and create an "I Want The Kit" user account. The unique code number will indicate the "I Want The Kit" user is referred from an emergency department patient who is an index participant. The index participants would also be informed of a lottery-based monetary compensation to provide 1 in 10 chance to win an additional $10 gift card for every "I Want The Kit" user that is referred from an index participant of this study. Participant who wins the $10 gift card will be notified via text message, followed by a phone call while participant who does not win the gift card will be notified via text message (see section 20 for "Text Message Script for Lottery Incentive). The confidential code numbers will allow determination of whether emergency department subjects and/or their referrals use the "I Want The Kit" website but will not allow research team access to identity-linked test results (Please see data management section below regarding de-identification before data analysis). At the 1-month and 3-month phone follow-up, the investigators will ask participants if they are able to give the referral cards to their partner(s) or friend(s), how many cards they are able to give out, how many cards they are able to give to their partner(s), how many cards they are able to give to their friend(s), and how likely it is that their partner(s) and/or friend(s) will request an HIV self-testing kit from the "I Want The Kit" website. Finally, the investigators will ask them how the investigators can increase the likelihood of their partner(s) and/or friend(s) accessing the "I Want The Kit" website and requesting an HIV self-testing kit. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |